Type 2 antifolates in the chemotherapy of falciparum malaria
Autor(a) principal: | |
---|---|
Data de Publicação: | 2002 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Journal of the Brazilian Chemical Society (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532002000600003 |
Resumo: | About 40% of the world population is exposed to malaria, which results in the death of over 2 million people per year in Africa, Latin America, Southern Asia and Oceania. The most severe type of malaria in humans is caused by the protozoan parasite Plasmodium falciparum. Chemotherapy is still one of the main control strategies for this parasite. Many of the antimalarials act by inhibiting the enzyme dihydrofolate reductase (DHFR), resulting in protozoan death. However, the development of drug resistance is reducing the efficiency of antifolates as antimalarials. This phenomenon has been linked to the occurrence of mutations in the dihydrofolate reductase of the parasite. This article includes a preliminary review of some of the features of falciparum malaria, followed by a more extensive review of the dihydrofolate reductase of P. falciparum and the mutations related to antifolate resistance. |
id |
SBQ-2_f2586805da528de6b921b223f50c52ab |
---|---|
oai_identifier_str |
oai:scielo:S0103-50532002000600003 |
network_acronym_str |
SBQ-2 |
network_name_str |
Journal of the Brazilian Chemical Society (Online) |
repository_id_str |
|
spelling |
Type 2 antifolates in the chemotherapy of falciparum malariamalariaPlasmodium falciparumdihydrofolate reductaseantifolate resistanceAbout 40% of the world population is exposed to malaria, which results in the death of over 2 million people per year in Africa, Latin America, Southern Asia and Oceania. The most severe type of malaria in humans is caused by the protozoan parasite Plasmodium falciparum. Chemotherapy is still one of the main control strategies for this parasite. Many of the antimalarials act by inhibiting the enzyme dihydrofolate reductase (DHFR), resulting in protozoan death. However, the development of drug resistance is reducing the efficiency of antifolates as antimalarials. This phenomenon has been linked to the occurrence of mutations in the dihydrofolate reductase of the parasite. This article includes a preliminary review of some of the features of falciparum malaria, followed by a more extensive review of the dihydrofolate reductase of P. falciparum and the mutations related to antifolate resistance.Sociedade Brasileira de Química2002-11-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532002000600003Journal of the Brazilian Chemical Society v.13 n.6 2002reponame:Journal of the Brazilian Chemical Society (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.1590/S0103-50532002000600003info:eu-repo/semantics/openAccessDelfino,Reinaldo T.Santos-Filho,Osvaldo A.Figueroa-Villar,José D.eng2015-11-26T00:00:00Zoai:scielo:S0103-50532002000600003Revistahttp://jbcs.sbq.org.brONGhttps://old.scielo.br/oai/scielo-oai.php||office@jbcs.sbq.org.br1678-47900103-5053opendoar:2015-11-26T00:00Journal of the Brazilian Chemical Society (Online) - Sociedade Brasileira de Química (SBQ)false |
dc.title.none.fl_str_mv |
Type 2 antifolates in the chemotherapy of falciparum malaria |
title |
Type 2 antifolates in the chemotherapy of falciparum malaria |
spellingShingle |
Type 2 antifolates in the chemotherapy of falciparum malaria Delfino,Reinaldo T. malaria Plasmodium falciparum dihydrofolate reductase antifolate resistance |
title_short |
Type 2 antifolates in the chemotherapy of falciparum malaria |
title_full |
Type 2 antifolates in the chemotherapy of falciparum malaria |
title_fullStr |
Type 2 antifolates in the chemotherapy of falciparum malaria |
title_full_unstemmed |
Type 2 antifolates in the chemotherapy of falciparum malaria |
title_sort |
Type 2 antifolates in the chemotherapy of falciparum malaria |
author |
Delfino,Reinaldo T. |
author_facet |
Delfino,Reinaldo T. Santos-Filho,Osvaldo A. Figueroa-Villar,José D. |
author_role |
author |
author2 |
Santos-Filho,Osvaldo A. Figueroa-Villar,José D. |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Delfino,Reinaldo T. Santos-Filho,Osvaldo A. Figueroa-Villar,José D. |
dc.subject.por.fl_str_mv |
malaria Plasmodium falciparum dihydrofolate reductase antifolate resistance |
topic |
malaria Plasmodium falciparum dihydrofolate reductase antifolate resistance |
description |
About 40% of the world population is exposed to malaria, which results in the death of over 2 million people per year in Africa, Latin America, Southern Asia and Oceania. The most severe type of malaria in humans is caused by the protozoan parasite Plasmodium falciparum. Chemotherapy is still one of the main control strategies for this parasite. Many of the antimalarials act by inhibiting the enzyme dihydrofolate reductase (DHFR), resulting in protozoan death. However, the development of drug resistance is reducing the efficiency of antifolates as antimalarials. This phenomenon has been linked to the occurrence of mutations in the dihydrofolate reductase of the parasite. This article includes a preliminary review of some of the features of falciparum malaria, followed by a more extensive review of the dihydrofolate reductase of P. falciparum and the mutations related to antifolate resistance. |
publishDate |
2002 |
dc.date.none.fl_str_mv |
2002-11-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532002000600003 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532002000600003 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0103-50532002000600003 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
dc.source.none.fl_str_mv |
Journal of the Brazilian Chemical Society v.13 n.6 2002 reponame:Journal of the Brazilian Chemical Society (Online) instname:Sociedade Brasileira de Química (SBQ) instacron:SBQ |
instname_str |
Sociedade Brasileira de Química (SBQ) |
instacron_str |
SBQ |
institution |
SBQ |
reponame_str |
Journal of the Brazilian Chemical Society (Online) |
collection |
Journal of the Brazilian Chemical Society (Online) |
repository.name.fl_str_mv |
Journal of the Brazilian Chemical Society (Online) - Sociedade Brasileira de Química (SBQ) |
repository.mail.fl_str_mv |
||office@jbcs.sbq.org.br |
_version_ |
1750318164962443264 |